Lilly Just Bet $2.3 Billion That a Failed Drug Class Deserves a Second Chance

Ajax tested AJ1-11095 in 23 patients with myelofibrosis (a serious blood cancer) who had already failed on existing JAK inhibitors. These are the toughest patients to treat: their disease had stopped responding to the standard playbook.

The results were striking. About 70% of patients (16 out of 23) achieved a 35% or greater reduction in spleen volume, a key measure of treatment response. For context, that's a remarkably high bar in a population where existing drugs had already stopped working.

But the spleen data wasn't even the headline. Driver-mutation levels dropped in 21 out of 23 patients. That's significant because it suggests the drug isn't just managing symptoms; it may be attacking the disease at its genetic root. First-generation JAK inhibitors rarely do that. They shrink spleens and ease symptoms, but the malignant cells keep chugging along underneath.

And on safety? No dose-limiting toxicities. No patients quit the trial because of drug-related side effects. For a class haunted by black box warnings, that early signal matters enormously.

Why Lilly, and Why Now?

This isn't Lilly stumbling into unfamiliar territory. The company has been on an immunology and oncology shopping spree, completing roughly 39 transactions in 2025 alone and deploying around $4 billion in capital. The Ajax deal is the third oncology-focused acquisition Lilly has announced in recent weeks.

Lilly also has history here. Lilly was actually a founding strategic investor in Ajax, participating in the company's Series C round back in 2024. They've been watching this science develop from the inside.

Scotiabank analyst Louise Chen highlighted that the acquisition strengthens Lilly's blood-cancer portfolio and diversifies the company beyond its dominant obesity and diabetes franchise. That diversification angle is key: Lilly's stock is so tightly linked to GLP-1 drugs like tirzepatide that investors are hungry for proof the company has more tricks up its sleeve.

Wall Street Shrugs (For Now)

The market reaction was, predictably, a yawn. Lilly shares dipped about 1.8% on the announcement. That's not alarm; that's investors mentally filing the deal under "interesting, tell me more later."

Analysts broadly agree the deal structure is sensible. The $2.3 billion figure is a ceiling, not a guarantee; Ajax shareholders get an upfront cash payment at closing, with the rest tied to clinical and regulatory milestones. If the drug stumbles in Phase 2 or Phase 3, Lilly doesn't pay the full tab.

RBC Capital Markets analyst Trung Huynh called the science "scientifically grounded" with a "clear strategic rationale," while noting the asset hadn't yet produced full proof-of-concept data at the time of the deal. Zacks maintains a Hold rating on Lilly, viewing Ajax as pipeline upside rather than a valuation game-changer.

The EHA data has since shifted that narrative somewhat. Lilly's oncology team has signaled plans to rapidly advance AJ1-11095 into Phase 3 for second-line myelofibrosis, a move analysts interpret as genuine confidence rather than corporate theater.

The Bigger Picture: Can You Fix a Broken Class?

This deal's significance extends well beyond one drug or one company.

The FDA's 2021 class-wide black box warning cast a long shadow over all JAK inhibitors, based largely on a single trial (ORAL Surveillance) that studied tofacitinib in older rheumatoid arthritis patients with pre-existing heart risk. Regulators then applied the same warning to every JAK drug on the market, reasoning that shared mechanism meant shared risk.

That logic made sense at the time. But it also created a massive opening for anyone who could prove the safety problems were about selectivity, not the entire JAK pathway. If Ajax's highly selective Type II approach continues to show clean safety data in larger trials, it could fundamentally reshape how regulators and doctors think about the class.

Lilly isn't the only one betting on this thesis. Bristol Myers Squibb's TYK2 inhibitor deucravacitinib already proved that selective JAK-pathway targeting can dodge the safety stigma. Companies like Nimbus, Priovant, Biohaven, and Incyte are all advancing next-gen selective approaches. The race is on to demonstrate that precision, not avoidance, is the right answer.

For Ajax's Type II JAK2 inhibitor specifically, the next milestone is clear: a larger, longer Phase 3 trial that proves what 23 patients hinted at. Spleen responses are encouraging. Mutation reductions are tantalizing. But durability, survival benefits, and long-term safety in hundreds of patients will determine whether Lilly's $2.3 billion ceiling was a bargain or a stretch.

The JAK inhibitor story was supposed to be a cautionary tale. Lilly is betting it's actually an origin story.

The First Toddlers Eligible for CRISPR Are Two Years Old

The FDA just approved a CRISPR gene therapy for kids as young as two, making Casgevy the first gene-editing treatment cleared for toddlers with sickle cell disease or beta thalassemia. The approval took just 53 days, and the implications stretch far beyond the 5,500 newly eligible children.